This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kappos, L Articles by Montalban, X Search for Related Content PubMed PubMed Citation Articles by Kappos, L Articles by Montalban, X Social Bookmarking                         What's this?

Towards a European Network for Multiple Sclerosis Trials (ENMST)

Outpatient Clinic Neurology-Neurosurgery, University Hospitals, Basel, Switzerland, lkappos{at}uhbs.ch

C Polman

Department of Neurology, Free University VU Medical Centre, Amsterdam, the Netherlands

A J Thompson

Department of Neurology, The National Hospital, London, UK

P Duda

Outpatient Clinic Neurology-Neurosurgery, University Hospitals, Basel, Switzerland

M Clanet

Department of Neurology, CHU Hospital Purpan, Toulouse, France

G Comi

Centro Sclerosi Multipla, Ospedale San Raffaele, Milan, Italy

H P Hartung

Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany

X Montalban

Department of Neuroimmunology, University Hospitals, Vall d’Hebron, Spain

Quality standards for clinical studies in the field of multiple sclerosis (MS) have improved significantly, to the great benefit of patients. This development has been accompanied by soaring costs and ever increasing complexity, with industry-independent trials having become virtually impossible. We propose establishing a European network that would include expertise in all the relevant aspects of MS treatment trials. In a stepwise approach, all interested active centres across Europe should be recruited into the network, based on agreement upon common scientific standards and quality requirements. Three main goals are discussed:

• • to facilitate identification of potentially useful agents for MS treatment;
  
• • to establish protocols for the interactio n between investigators and industry; and
  
• • to identify common standards and a core set of data to allow for comparisons of MS trials.
  Collaboration with existing international organizations and institutions, especially the Sylvia Lawry Centre for MS Research, as well as with similar initiatives in North A merica and other parts of the world is envisaged.
  

Key Words: clinical trials • methods • multiple sclerosis • quality standards

Multiple Sclerosis, Vol. 9, No. 6, 627-629 (2003)
DOI: 10.1191/1352458503ms962xx


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Kappos, A. Traboulsee, C. Constantinescu, J. -P. Eralinna, F. Forrestal, P. Jongen, J. Pollard, M. Sandberg-Wollheim, C. Sindic, B. Stubinski, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology, September 26, 2006; 67(6): 944 - 953. [Abstract] [Full Text] [PDF]

				J. Cohen, G. Cutter, F. Lublin, and S. Schwid The MS Co-O perative Research (MS-CORE) group: an alternate approach to fostering multicenter studies Multiple Sclerosis, June 1, 2004; 10(3): 332 - 335. [PDF]